DOP2021000035A - INHIBICION DE LA INTEGRINA AVß6 - Google Patents

INHIBICION DE LA INTEGRINA AVß6

Info

Publication number
DOP2021000035A
DOP2021000035A DO2021000035A DO2021000035A DOP2021000035A DO P2021000035 A DOP2021000035 A DO P2021000035A DO 2021000035 A DO2021000035 A DO 2021000035A DO 2021000035 A DO2021000035 A DO 2021000035A DO P2021000035 A DOP2021000035 A DO P2021000035A
Authority
DO
Dominican Republic
Prior art keywords
integrin
assay
avß6
inhibition
compounds
Prior art date
Application number
DO2021000035A
Other languages
English (en)
Inventor
N Rogers Bruce
A Harrison Bryce
E Dowling James
I Gerasyuto Aleksey
G Bursavich Matthew
M Troast Dawn
S Lippa Blaise
N Hahn Kristopher
Zhong Cheng
Qiao Qi
Lin Fu-Yang
Sosa Brian
Bortolato Andrea
A Svensson Mats
Hickey Eugene
D Konze Kyle
Day Tyler
Kim Byungchan
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of DOP2021000035A publication Critical patent/DOP2021000035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

Se describen inhibidores de molécula pequeña de la integrina a¿ß6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina a¿ß6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de a¿ß6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
DO2021000035A 2018-08-29 2021-02-25 INHIBICION DE LA INTEGRINA AVß6 DOP2021000035A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10
PCT/US2019/048782 WO2020047239A1 (en) 2018-08-29 2019-08-29 INHIBITING αV β6 INTEGRIN

Publications (1)

Publication Number Publication Date
DOP2021000035A true DOP2021000035A (es) 2021-06-30

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000035A DOP2021000035A (es) 2018-08-29 2021-02-25 INHIBICION DE LA INTEGRINA AVß6

Country Status (22)

Country Link
US (4) US20200071322A1 (es)
EP (2) EP4086254A1 (es)
JP (1) JP2021535141A (es)
KR (1) KR20210065935A (es)
CN (1) CN112805001A (es)
AU (1) AU2019327475A1 (es)
BR (1) BR112021003859A2 (es)
CA (1) CA3109534A1 (es)
CL (1) CL2021000484A1 (es)
CO (1) CO2021002706A2 (es)
CR (1) CR20210109A (es)
DO (1) DOP2021000035A (es)
EC (1) ECSP21013620A (es)
IL (1) IL280782A (es)
MA (1) MA51066A (es)
MX (1) MX2021002181A (es)
PE (1) PE20211640A1 (es)
PH (1) PH12021550404A1 (es)
SG (1) SG11202101913PA (es)
TW (1) TW202035400A (es)
UY (1) UY38353A (es)
WO (1) WO2020047239A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EA202190134A1 (ru) 2018-06-27 2021-03-26 Плайэнт Терапьютикс, Инк. Соединения аминокислот с неразветвленными линкерами и способы их применения
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
CR20210213A (es) 2018-10-30 2021-06-24 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CN116323633A (zh) * 2020-09-11 2023-06-23 箭头药业股份有限公司 骨骼肌递送平台及使用方法

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH07501063A (ja) 1991-11-14 1995-02-02 グラクソ、グループ、リミテッド フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
JPH07503459A (ja) 1992-01-21 1995-04-13 グラクソ、グループ、リミテッド 酢酸誘導体
EP0623615B1 (de) 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU1353897A (en) 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024124A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP0880511A4 (en) 1996-01-16 1999-06-16 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
EP0796855B1 (de) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
EP0946165B1 (en) 1996-10-30 2003-04-09 Merck & Co., Inc. Integrin antagonists
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
AU7105498A (en) 1997-04-14 1998-11-11 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
WO1999030713A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
AU741769B2 (en) 1997-12-17 2001-12-06 Merck Sharp & Dohme Corp. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002521450A (ja) 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CA2355874A1 (en) 1998-12-19 2000-06-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung .alpha.v.beta.6 integrin inhibitors
WO2000046215A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2000072801A2 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20050004199A1 (en) 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
RU2333210C2 (ru) 2002-08-16 2008-09-10 Янссен Фармацевтика Н.В. Соединения пиперидинила, селективно связывающие интегрины
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
JP6215324B2 (ja) 2012-07-18 2017-10-18 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
WO2016022851A1 (en) 2014-08-06 2016-02-11 Children's Medical Center Corporation Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016219906B2 (en) 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
RU2017141561A (ru) 2015-04-30 2019-05-31 Сайфлуор Лайф Сайенсиз, Инк. Производные тетрагидронафтиридинилпропионовой кислоты и их применение
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2018009501A1 (en) 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
KR102634762B1 (ko) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
WO2018085552A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2018085578A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
EP3538526B1 (en) 2016-11-08 2024-04-10 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
LT3538525T (lt) 2016-11-08 2022-09-26 Bristol-Myers Squibb Company Propiono rūgštys, pakeistos 3 padėtyje, kaip alfa v integrino inhibitoriai
AU2017359027A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
US10717736B2 (en) 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
CA3042684A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as .alpha.v integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
RU2019116820A (ru) 2016-12-29 2021-01-29 Сент-Луис Юниверсити Антагонисты интегрина
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EA202190134A1 (ru) 2018-06-27 2021-03-26 Плайэнт Терапьютикс, Инк. Соединения аминокислот с неразветвленными линкерами и способы их применения
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
EP3843728A4 (en) 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CA3136745A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Also Published As

Publication number Publication date
MA51066A (fr) 2020-10-14
US11739087B2 (en) 2023-08-29
CN112805001A (zh) 2021-05-14
US20200071322A1 (en) 2020-03-05
US11021480B2 (en) 2021-06-01
CA3109534A1 (en) 2020-03-05
UY38353A (es) 2020-03-31
PE20211640A1 (es) 2021-08-24
MX2021002181A (es) 2021-07-15
EP4086254A1 (en) 2022-11-09
WO2020047239A1 (en) 2020-03-05
SG11202101913PA (en) 2021-03-30
ECSP21013620A (es) 2021-05-31
EP3617206A1 (en) 2020-03-04
CO2021002706A2 (es) 2021-05-20
BR112021003859A2 (pt) 2021-05-18
CL2021000484A1 (es) 2021-09-03
KR20210065935A (ko) 2021-06-04
AU2019327475A1 (en) 2021-03-11
JP2021535141A (ja) 2021-12-16
PH12021550404A1 (en) 2021-10-04
IL280782A (en) 2021-04-29
US20220073511A1 (en) 2022-03-10
US20200385384A1 (en) 2020-12-10
US20200354359A1 (en) 2020-11-12
CR20210109A (es) 2021-06-24
TW202035400A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
DOP2021000035A (es) INHIBICION DE LA INTEGRINA AVß6
WO2020047207A8 (en) Inhibitors of (alpha-v)(beta-6) integrin
CU24387B1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
ECSP11010889A (es) INHIBIDORES DE cMET
BRPI0911105A2 (pt) compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seu uso
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
ECSP10010129A (es) Inhibidores de quinasas símil polo
PE20211478A1 (es) Formas cristalinas novedosas
UY31261A1 (es) Imidazopiridinonas, composiciones que las contienen, procedimientos para su preparacion, intermedios utilizados en tales procedimientos y aplicaciones.
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
UY29479A1 (es) Inhibidores de adn-pk
CR11492A (es) Peptidil nitrilos y uso de los mismos como inhibidores de dipeptidil peptidasa i
CR9664A (es) Inhibidores de histona deacetilasa
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CR20140217A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii
UY31479A1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2020004554A (es) Ligandos de integrina y usos de estos.
CO2018001264A2 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos
ECSP23051657A (es) Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
GT200500382A (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2, composicion farmaceutica que comprende estos compuestos, metodo de prepararlos y su uso
MX2020009022A (es) Uso de alcoxipirazoles como inhibidores de la nitrificacion.